What is the current Price Target for the Vivoryon Therapeutics stock?

The average Vivoryon Therapeutics target price is €5.33. This is 170.73% higher than the current stock price. The highest price target is 356.85%, the lowest is 1.52%. 3 Analysts have issued a price target Vivoryon Therapeutics 2026 .

How high will the Vivoryon Therapeutics stock rise?

No reliable answer can be given as to how high the Vivoryon Therapeutics stock will rise. The performance of stocks, including the Vivoryon Therapeutics stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Vivoryon Therapeutics stock today?

The performance of Vivoryon Therapeutics stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Vivoryon Therapeutics stock fall?

The decline in Vivoryon Therapeutics stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Vivoryon Therapeutics Forecast, price target & analysts

€1.98

0.51% today

Amsterdam, Feb 28, 05:35 pm CET

ISIN

NL00150002Q7

Symbol

VVY

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts Strategies

Vivoryon Therapeutics Target price 2025 - Analyst rating & recommendation

Vivoryon Therapeutics Classifications & Recommendation:

Buy

33%

Hold

67%

Vivoryon Therapeutics Price Target

Target Price	€5.33
Price	€1.97
Potential	170.73% register free of charge
Number of Estimates	3

	3 Analysts have issued a price target Vivoryon Therapeutics 2026 . The average Vivoryon Therapeutics target price is €5.33. This is 170.73% register free of charge higher than the current stock price. The highest price target is €9.00 356.85% register free of charge , the lowest is €2.00 1.52% register free of charge .
	A rating was issued by 3 analysts: 1 Analysts recommend Vivoryon Therapeutics to buy, 2 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Vivoryon Therapeutics stock has an average upside potential 2026 of 170.73% register free of charge . Most analysts recommend the Vivoryon Therapeutics stock at Hold.

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Annually

	Dec '23	2024 Estimates
Earnings Per Share €	-1.12	-0.90
	12.50%	19.64%
P/E		negative

1 Analysts have issued a Vivoryon Therapeutics forecast for earnings per share. The average Vivoryon Therapeutics <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2023	€-1.12	12.50%
2024	€-0.90 19.64% Unlock
2025	€-0.70 22.22% Unlock
2026	€-0.70 0.00% Unlock

Current	-1.65	79.93%
2024	-2.19 32.73% Unlock
2025	-2.81 28.31% Unlock
2026	-2.81 0.00% Unlock

Vivoryon Therapeutics...

Current Vivoryon Therapeutics Upgrades & Downgrades Beta

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
RX SECURITIES	Locked ➜ Locked	Locked	Jan 05 2025

Analyst Rating	Date
Locked RX SECURITIES: Locked ➜ Locked	Jan 05 2025

Discover more stocks with a high price target

Coinbase Global, Inc. 60.51%

BioNTech SE - ADR 30.07%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now